Seek Returns logo

PODD vs. RGC: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at PODD and RGC, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

SymbolPODDRGC
Company NameInsulet CorporationRegencell Bioscience Holdings Limited
CountryUnited StatesHong Kong
GICS SectorHealth CareHealth Care
GICS IndustryHealth Care Equipment & SuppliesPharmaceuticals
Market Capitalization22.38 billion USD7.83 billion USD
ExchangeNasdaqGSNasdaqCM
Listing DateMay 15, 2007July 16, 2021
Security TypeCommon StockCommon Stock

Historical Performance

This chart compares the performance of PODD and RGC by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

PODD vs. RGC: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolPODDRGC
5-Day Price Return-5.58%5.97%
13-Week Price Return-1.73%-9.33%
26-Week Price Return16.55%1,414.71%
52-Week Price Return33.06%10,200.00%
Month-to-Date Return-9.17%9.96%
Year-to-Date Return18.26%11,784.62%
10-Day Avg. Volume0.73M0.19M
3-Month Avg. Volume0.70M1.06M
3-Month Volatility31.33%266.49%
Beta1.402.25

Profitability

Return on Equity (TTM)

PODD

18.43%

Health Care Equipment & Supplies Industry

Max
29.93%
Q3
16.99%
Median
9.28%
Q1
5.10%
Min
-12.52%

In the upper quartile for the Health Care Equipment & Supplies industry, PODD’s Return on Equity of 18.43% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

RGC

-54.75%

Pharmaceuticals Industry

Max
38.59%
Q3
19.84%
Median
11.85%
Q1
5.40%
Min
-10.91%

RGC has a negative Return on Equity of -54.75%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

PODD vs. RGC: A comparison of their Return on Equity (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Net Profit Margin (TTM)

PODD

10.01%

Health Care Equipment & Supplies Industry

Max
24.41%
Q3
13.71%
Median
10.08%
Q1
5.96%
Min
-5.58%

PODD’s Net Profit Margin of 10.01% is aligned with the median group of its peers in the Health Care Equipment & Supplies industry. This indicates its ability to convert revenue into profit is typical for the sector.

RGC

--

Pharmaceuticals Industry

Max
40.67%
Q3
19.07%
Median
12.31%
Q1
4.50%
Min
-9.91%

Net Profit Margin data for RGC is currently unavailable.

PODD vs. RGC: A comparison of their Net Profit Margin (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Operating Profit Margin (TTM)

PODD

12.01%

Health Care Equipment & Supplies Industry

Max
31.09%
Q3
18.11%
Median
15.07%
Q1
8.48%
Min
-0.28%

PODD’s Operating Profit Margin of 12.01% is around the midpoint for the Health Care Equipment & Supplies industry, indicating that its efficiency in managing core business operations is typical for the sector.

RGC

--

Pharmaceuticals Industry

Max
45.78%
Q3
23.14%
Median
16.68%
Q1
7.98%
Min
-7.13%

Operating Profit Margin data for RGC is currently unavailable.

PODD vs. RGC: A comparison of their Operating Profit Margin (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Profitability at a Glance

SymbolPODDRGC
Return on Equity (TTM)18.43%-54.75%
Return on Assets (TTM)7.21%-51.38%
Net Profit Margin (TTM)10.01%--
Operating Profit Margin (TTM)12.01%--
Gross Profit Margin (TTM)70.74%--

Financial Strength

Current Ratio (MRQ)

PODD

2.26

Health Care Equipment & Supplies Industry

Max
5.19
Q3
3.00
Median
2.13
Q1
1.44
Min
0.86

PODD’s Current Ratio of 2.26 aligns with the median group of the Health Care Equipment & Supplies industry, indicating that its short-term liquidity is in line with its sector peers.

RGC

42.68

Pharmaceuticals Industry

Max
4.65
Q3
2.64
Median
1.85
Q1
1.26
Min
0.78

RGC’s Current Ratio of 42.68 is exceptionally high, placing it well outside the typical range for the Pharmaceuticals industry. This indicates a very strong liquidity position, though such a high ratio may also suggest that the company is not using its assets efficiently to generate profits.

PODD vs. RGC: A comparison of their Current Ratio (MRQ) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Debt-to-Equity Ratio (MRQ)

PODD

0.96

Health Care Equipment & Supplies Industry

Max
1.61
Q3
0.76
Median
0.45
Q1
0.14
Min
0.00

PODD’s leverage is in the upper quartile of the Health Care Equipment & Supplies industry, with a Debt-to-Equity Ratio of 0.96. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.

RGC

0.00

Pharmaceuticals Industry

Max
1.75
Q3
0.82
Median
0.35
Q1
0.13
Min
0.00

Falling into the lower quartile for the Pharmaceuticals industry, RGC’s Debt-to-Equity Ratio of 0.00 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.

PODD vs. RGC: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Interest Coverage Ratio (TTM)

PODD

33.28

Health Care Equipment & Supplies Industry

Max
56.35
Q3
25.56
Median
9.60
Q1
3.78
Min
-26.49

PODD’s Interest Coverage Ratio of 33.28 is in the upper quartile for the Health Care Equipment & Supplies industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.

RGC

--

Pharmaceuticals Industry

Max
103.95
Q3
43.60
Median
9.83
Q1
2.37
Min
-42.71

Interest Coverage Ratio data for RGC is currently unavailable.

PODD vs. RGC: A comparison of their Interest Coverage Ratio (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Financial Strength at a Glance

SymbolPODDRGC
Current Ratio (MRQ)2.2642.68
Quick Ratio (MRQ)1.5541.89
Debt-to-Equity Ratio (MRQ)0.960.00
Interest Coverage Ratio (TTM)33.28--

Growth

Revenue Growth

PODD vs. RGC: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

PODD vs. RGC: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

PODD

0.00%

Health Care Equipment & Supplies Industry

Max
4.15%
Q3
1.76%
Median
0.79%
Q1
0.00%
Min
0.00%

PODD currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

RGC

0.00%

Pharmaceuticals Industry

Max
7.14%
Q3
3.45%
Median
2.17%
Q1
0.33%
Min
0.00%

RGC currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

PODD vs. RGC: A comparison of their Dividend Yield (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Dividend Payout Ratio (TTM)

PODD

0.00%

Health Care Equipment & Supplies Industry

Max
160.00%
Q3
66.60%
Median
27.49%
Q1
0.00%
Min
0.00%

PODD has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

RGC

0.00%

Pharmaceuticals Industry

Max
199.58%
Q3
97.17%
Median
53.47%
Q1
22.97%
Min
0.00%

RGC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

PODD vs. RGC: A comparison of their Dividend Payout Ratio (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Dividend at a Glance

SymbolPODDRGC
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

Price-to-Earnings Ratio (TTM)

PODD

92.77

Health Care Equipment & Supplies Industry

Max
67.29
Q3
47.01
Median
30.94
Q1
23.91
Min
10.79

At 92.77, PODD’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Health Care Equipment & Supplies industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.

RGC

--

Pharmaceuticals Industry

Max
45.19
Q3
27.91
Median
20.59
Q1
15.08
Min
3.79

P/E Ratio data for RGC is currently unavailable.

PODD vs. RGC: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Price-to-Sales Ratio (TTM)

PODD

9.28

Health Care Equipment & Supplies Industry

Max
9.49
Q3
5.41
Median
2.86
Q1
2.07
Min
0.74

PODD’s P/S Ratio of 9.28 is in the upper echelon for the Health Care Equipment & Supplies industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.

RGC

--

Pharmaceuticals Industry

Max
8.87
Q3
4.56
Median
2.14
Q1
1.58
Min
0.11

P/S Ratio data for RGC is currently unavailable.

PODD vs. RGC: A comparison of their Price-to-Sales Ratio (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Price-to-Book Ratio (MRQ)

PODD

15.11

Health Care Equipment & Supplies Industry

Max
10.85
Q3
6.56
Median
3.53
Q1
2.36
Min
0.71

At 15.11, PODD’s P/B Ratio is at an extreme premium to the Health Care Equipment & Supplies industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

RGC

9.57

Pharmaceuticals Industry

Max
9.78
Q3
4.99
Median
2.48
Q1
1.53
Min
0.59

RGC’s P/B Ratio of 9.57 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.

PODD vs. RGC: A comparison of their Price-to-Book Ratio (MRQ) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Valuation at a Glance

SymbolPODDRGC
Price-to-Earnings Ratio (TTM)92.77--
Price-to-Sales Ratio (TTM)9.28--
Price-to-Book Ratio (MRQ)15.119.57
Price-to-Free Cash Flow Ratio (TTM)57.28--